Effects of alpha-lipoic acid in an animal model of mania induced by d-amphetamine

Bipolar Disorders

Volumn 14, Issue 7, 2012, Pages 707-718

  Macêdo, Danielle S ^a   Medeiros, Camila D ^a   Cordeiro, Rafaela C ^a   Sousa, Francisca Cléa ^a   Santos, Júnia V ^a   Morais, Thomás A ^a   Hyphantis, Thomas N ^b   Mcintyre, Roger S ^c,d   Quevedo, João ^e   Carvalho, André F ^a  

^a FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^b UNIVERSITY OF IOANNINA   (Greece)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

^e UNIVERSITY OF SOUTHERN SANTA CATARINA   (Brazil)

Author keywords

Alpha lipoic acid; Brain derived neurotrophic factor; D amphetamine; Mania; Oxidative stress

Indexed keywords

AMPHETAMINE; BRAIN DERIVED NEUROTROPHIC FACTOR; GLUTATHIONE; LITHIUM; SODIUM CHLORIDE; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; THIOCTIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR CHANGE; BRAIN REGION; CLINICAL PROTOCOL; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE MODEL; DRUG EFFECT; ENZYME ACTIVITY; HIPPOCAMPUS; LOCOMOTION; MALE; MANIA; MOUSE; NONHUMAN; OPEN FIELD TEST; OUTCOME ASSESSMENT; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ANIMALS; ANTIMANIC AGENTS; BIPOLAR DISORDER; BRAIN; BRAIN-DERIVED NEUROTROPHIC FACTOR; CENTRAL NERVOUS SYSTEM STIMULANTS; DEXTROAMPHETAMINE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; GLUTATHIONE; LIPID PEROXIDATION; LITHIUM CHLORIDE; MALE; MALONDIALDEHYDE; MICE; MOTOR ACTIVITY; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCES; THIOCTIC ACID;

EID: 84868132717     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/j.1399-5618.2012.01046.x     Document Type: Article

References (70)

1. Belmaker RH. Bipolar disorder. N Engl J Med 2004; 351: 476-486.
2. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997; 349: 1498-1504.
3. Harris EC, Barraclough B. Suicide as an outcome for mental disorders. A meta-analysis. Br J Psychiatry 1997; 170: 205-228.
4. Angst F, Stassen HH, Clayton PJ, Angst J. Mortality of patients with mood disorders: follow-up over 34-38years. J Affect Disord 2002; 68: 167-181.
5. Savitz J, Drevets WC. Bipolar and major depressive disorder: neuroimaging the developmental-degenerative divide. Neurosci Biobehav Rev 2009; 33: 699-771.
6. Berk M, Kapczinski F, Andreazza AC et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation; oxidative stress and neurotrophic factors. Neurosci Biobehav Rev 2011; 35: 804-817.
7. Steckert AV, Valvassori SS, Moretti M, Dal-Pizzol F, Quevedo J. Role of oxidative stress in the pathophysiology of bipolar disorder. Neurochem Res 2010; 35: 1295-1301.
8. Biewenga GP, Haenen GR, Bast A. The pharmacology of the antioxidant lipoic acid. Gen Pharmacol 1997; 29: 315-331.
9. Zecca L, Youdim MB, Riederer P, Connor JR, Crichton RR. Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 2004; 5: 863-873.
10. Gawryluk JW, Wang JF, Andreazza AC, Shao L, Young LT. Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders. Int J Neuropsychopharmacol 2011; 14: 123-130.
11. Che Y, Wang JF, Shao L, Young LT. Oxidative damage to RNA but not DNA in the hippocampus of patients with major mental illness. J Psychiatry Neurosci 2010; 35: 296-302.
12. Kato T, Kato N. Mitochondrial dysfunction in bipolar disorder. Bipolar Disord 2000; 2: 180-190.
13. Konradi C, Eaton M, MacDonald ML, Walsh J, Benes FM, Heckers S. Molecular evidence for mitochondrial dysfunction in bipolar disorder. Arch Gen Psychiatry 2004; 61: 300-308.
14. Post RM. Role of BDNF in bipolar and unipolar disorder: clinical and theoretical implications. J Psychiatr Res 2007; 41: 979-990.
15. Fernandes BS, Gama CS, Maria Cereser K et al. Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: a systematic review and meta-regression analysis. J Psychiatr Res 2011; 45: 995-1004.
16. Frey BN, Andreazza AC, Rosa AR et al. Lithium increases nerve growth factor levels in the rat hippocampus in an animal model of mania. Behav Pharmacol 2006; 17: 311-318.
17. Fukumoto T, Morinobu S, Okamoto Y, Kagaya A, Yamawaki S. Chronic lithium treatment increases the expression of brain-derived neurotrophic factor in the rat brain. Psychopharmacology (Berl) 2001; 158: 100-106.
18. Kapczinski F, Frey BN, Andreazza AC, Kauer-Sant'Anna M, Cunha AB, Post RM. Increased oxidative stress as a mechanism for decreased BDNF levels in acute manic episodes. Rev Bras Psiquiatr 2008; 30: 243-245.
19. Gould TD, Einat H. Animal models of bipolar disorder and mood stabilizer efficacy: a critical need for improvement. Neurosci Biobehav Rev 2007; 31: 825-831.
20. Frey BN, Martins MR, Petronilho FC, Dal-Pizzol F, Quevedo J, Kapczinski F. Increased oxidative stress after repeated amphetamine exposure: possible relevance as a model of mania. Bipolar Disord 2006; 8: 275-280.
21. Frey BN, Valvassori SS, Reus GZ et al. Effects of lithium and valproate on amphetamine-induced oxidative stress generation in an animal model of mania. J Psychiatry Neurosci 2006; 31: 326-332.
22. Reed LJ, De BB, Gunsalus IC, Hornberger CS Jr. Crystalline alpha-lipoic acid; a catalytic agent associated with pyruvate dehydrogenase. Science 1951; 114: 93-94.
23. Suzuki YJ, Tsuchiya M, Packer L. Thioctic acid and dihydrolipoic acid are novel antioxidants which interact with reactive oxygen species. Free Radic Res Commun 1991; 15: 255-263.
24. Salazar MR. Alpha lipoic acid: a novel treatment for depression. Med Hypotheses 2000; 55: 510-512.
25. Fuchs J. PL, Zimmer G. Lipoic Acid in Health and Disease. New York: Marcel Dekker Inc., 1997.
26. Shay KP, Moreau RF, Smith EJ, Smith AR, Hagen TM. Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential. Biochim Biophys Acta 2009; 1790: 1149-1160.
27. NIH. Guide for the Care and Use of Laboratory Animals-National Research Council, 8th edn. Washington, DC: The National Academies Press, 2011.
28. Hopkins HS, Gelenberg AJ. Serum lithium levels and the outcome of maintenance therapy of bipolar disorder. Bipolar Disord 2000; 2: 174-179.
29. Archer J. Tests for emotionality in rats and mice: a review. Anim Behav 1973; 21: 205-235.
30. Valvassori SS, Elias G, de Souza B et al. Effects of cannabidiol on amphetamine-induced oxidative stress generation in an animal model of mania. J Psychopharmacol 2010; 25: 274-280.
31. Sun M, Zigman S. An improved spectrophotometric assay for superoxide dismutase based on epinephrine autoxidation. Anal Biochem 1978; 90: 81-89.
32. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254.
33. Sedlak J, Hanus L. Changes of glutathione and protein bound SH-groups concentration in rat adrenals under acute and repeated stress. Endocrinol Exp 1982; 16: 103-109.
34. Draper HH, Squires EJ, Mahmoodi H, Wu J, Agarwal S, Hadley M. A comparative evaluation of thiobarbituric acid methods for the determination of malondialdehyde in biological materials. Free Radic Biol Med 1993; 15: 353-363.
35. Frey BN, Valvassori SS, Reus GZ et al. Changes in antioxidant defense enzymes after d-amphetamine exposure: implications as an animal model of mania. Neurochem Res 2006; 31: 699-703.
36. Frey BN, Andreazza AC, Cereser KM et al. Effects of mood stabilizers on hippocampus BDNF levels in an animal model of mania. Life Sci 2006; 79: 281-286.
37. El-Mallakh RS, Decker S, Morris M et al. Efficacy of olanzapine and haloperidol in an animal model of mania. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 1261-1264.
38. Krishnan V, Nestler EJ. Linking molecules to mood: new insight into the biology of depression. Am J Psychiatry 2010; 167: 1305-1320.
39. Fleckenstein AE, Volz TJ, Riddle EL, Gibb JW, Hanson GR. New insights into the mechanism of action of amphetamines. Annu Rev Pharmacol Toxicol 2007; 47: 681-698.
40. Fleckenstein AE, Metzger RR, Beyeler ML, Gibb JW, Hanson GR. Oxygen radicals diminish dopamine transporter function in rat striatum. Eur J Pharmacol 1997; 334: 111-114.
41. Volz TJ, Schenk JO. L-arginine increases dopamine transporter activity in rat striatum via a nitric oxide synthase-dependent mechanism. Synapse 2004; 54: 173-182.
42. Yamato M, Kudo W, Shiba T, Yamada KI, Watanabe T, Utsumi H. Determination of reactive oxygen species associated with the degeneration of dopaminergic neurons during dopamine metabolism. Free Radic Res 2010; 44: 249-257.
43. Berman SB, Hastings TG. Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson's disease. J Neurochem 1999; 73: 1127-1137.
44. Graham DG, Tiffany SM, Bell WR Jr, Gutknecht WF. Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. Mol Pharmacol 1978; 14: 644-653.
45. Rees JN, Florang VR, Anderson DG, Doorn JA. Lipid peroxidation products inhibit dopamine catabolism yielding aberrant levels of a reactive intermediate. Chem Res Toxicol 2007; 20: 1536-1542.
46. Obata T. Dopamine efflux by MPTP and hydroxyl radical generation. J Neural Transm 2002; 109: 1159-1180.
47. Stokes AH, Hastings TG, Vrana KE. Cytotoxic and genotoxic potential of dopamine. J Neurosci Res 1999; 55: 659-665.
48. Berk M, Dodd S, Kauer-Sant'anna M et al. Dopamine dysregulation syndrome: implications for a dopamine hypothesis of bipolar disorder. Acta Psychiatr Scand Suppl 2007: 41-49.
49. Berk M, Conus P, Kapczinski F et al. From neuroprogression to neuroprotection: implications for clinical care. Med J Aust 2010; 193: S36-S40.
50. Gross SS, Wolin MS. Nitric oxide: pathophysiological mechanisms. Annu Rev Physiol 1995; 57: 737-769.
51. Packer L, Witt EH, Tritschler HJ. alpha-Lipoic acid as a biological antioxidant. Free Radic Biol Med 1995; 19: 227-250.
52. Holmquist L, Stuchbury G, Berbaum K et al. Lipoic acid as a novel treatment for Alzheimer's disease and related dementias. Pharmacol Ther 2007; 113: 154-164.
53. Andreassen OA, Ferrante RJ, Dedeoglu A, Beal MF. Lipoic acid improves survival in transgenic mouse models of Huntington's disease. NeuroReport 2001; 12: 3371-3373.
54. Quinn JF, Bussiere JR, Hammond RS et al. Chronic dietary alpha-lipoic acid reduces deficits in hippocampal memory of aged Tg2576 mice. Neurobiol Aging 2007; 28: 213-225.
55. Stoll S, Hartmann H, Cohen SA, Muller WE. The potent free radical scavenger alpha-lipoic acid improves memory in aged mice: putative relationship to NMDA receptor deficits. Pharmacol Biochem Behav 1993; 46: 799-805.
56. Hagen TM, Ingersoll RT, Lykkesfeldt J et al. (R)-alpha-lipoic acid-supplemented old rats have improved mitochondrial function, decreased oxidative damage, and increased metabolic rate. FASEB J 1999; 13: 411-418.
57. Deslauriers J, Lefrancois M, Larouche A, Sarret P, Grignon S. Antipsychotic-induced DRD2 upregulation and its prevention by alpha-lipoic acid in SH-SY5Y neuroblastoma cells. Synapse 2011; 65: 321-331.
58. Halliwell B. Oxidative stress in cell culture: an under-appreciated problem? FEBS Lett 2003; 540: 3-6.
59. Leist M, Raab B, Maurer S, Rosick U, Brigelius-Flohe R. Conventional cell culture media do not adequately supply cells with antioxidants and thus facilitate peroxide-induced genotoxicity. Free Radic Biol Med 1996; 21: 297-306.
60. Chavez C, Gogos A, Jones ME, van den Buuse M. Psychotropic drug-induced locomotor hyperactivity and prepulse inhibition regulation in male and female aromatase knockout (ArKO) mice: role of dopamine D1 and D2 receptors and dopamine transporters. Psychopharmacology (Berl) 2009; 206: 267-279.
61. Zou YF, Wang F, Feng XL et al. Association of DRD2 gene polymorphisms with mood disorders: a meta-analysis. J Affect Disord 2012; 136: 229-237.
62. Santos IM, de Freitas RL, Saldanha GB, Tome Ada R, Jordan J, de Freitas RM. Alterations on monoamines concentration in rat hippocampus produced by lipoic acid. Arq Neuropsiquiatr 2010; 68: 362-366.
63. Andreazza AC, Shao L, Wang JF, Young LT. Mitochondrial complex I activity and oxidative damage to mitochondrial proteins in the prefrontal cortex of patients with bipolar disorder. Arch Gen Psychiatry 67: 360-368.
64. McIntosh AM, Whalley HC, McKirdy J et al. Prefrontal function and activation in bipolar disorder and schizophrenia. Am J Psychiatry 2008; 165: 378-384.
65. Frey BN, Andreazza AC, Nery FG et al. The role of hippocampus in the pathophysiology of bipolar disorder. Behav Pharmacol 2007; 18: 419-430.
66. Carvalho F, Fernandes E, Remiao F, Gomes-Da-Silva J, Tavares MA, Bastos MD. Adaptative response of antioxidant enzymes in different areas of rat brain after repeated d-amphetamine administration. Addict Biol 2001; 6: 213-221.
67. Iida M, Miyazaki I, Tanaka K, Kabuto H, Iwata-Ichikawa E, Ogawa N. Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist. Brain Res 1999; 838: 51-59.
68. Dean OM, van den Buuse M, Berk M, Copolov DL, Mavros C, Bush AI. N-acetyl cysteine restores brain glutathione loss in combined 2-cyclohexene-1-one and d-amphetamine-treated rats: relevance to schizophrenia and bipolar disorder. Neurosci Lett 2011; 499: 149-153.
69. Mecocci P, Beal MF, Cecchetti R et al. Mitochondrial membrane fluidity and oxidative damage to mitochondrial DNA in aged and AD human brain. Mol Chem Neuropathol 1997; 31: 53-64.
70. Arivazhagan P, Panneerselvam C. Effect of DL-alpha-lipoic acid on the status of lipids and membrane-bound ATPases in various brain regions of aged rats. J Anti Aging Med 2002; 5: 335-343.